Skip to main content

Percutaneous cryoablation for local control of breast cancer in patients unsuitable for conventional surgery: a prospective study

In brief

Cryoablation left treated breast tumors recurrence-free at one year in 20 patients

In this prospective study, all 20 patients had complete ablation, and one-year imaging found no recurrence in the treated area; one patient developed multifocal disease elsewhere in the breast. Procedures were completed in 95%, with minor complications in 10%. The small study supports feasibility for patients unfit for surgery, but longer follow-up is needed.

Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (Q1)
Published
12 October 2026
Study design
Cohort / observational study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Yuk-Kwan Chang, Ava Kwong
PMID
43019826
DOI
10.1016/j.ejso.2026.112213

Why clinicians should know about it

  • Picked for Breast and Endocrine Surgery (paper of the day, 13 November 2026): Prospective breast cryoablation study for patients unsuitable for surgery

Abstract

BACKGROUND: Breast cancer is the most common malignancy among women and a leading cause of cancer-related mortality. Management in elderly or medically frail patients is often limited by comorbidities and surgical risk. Cryoablation provides a minimally invasive option for local disease control under local anaesthesia; however, evidence supporting its use in palliative settings remains limited. This study aimed to assess the safety, feasibility, and radiological response of percutaneous cryoablation in patients unsuitable for conventional surgery or general anaesthesia. METHODS: In this prospective study, consecutive patients with histologically confirmed invasive carcinoma or ductal carcinoma in situ (DCIS) ≤ 3 cm were included if they had radiologically stable metastatic disease or were medically unfit for surgery. All underwent ultrasound-guided cryoablation using the IceCure ProSense™ system under local anaesthesia or monitored anaesthetic care. The primary endpoint was complete radiological response at one year; secondary outcomes included procedural success, same-day discharge, pain scores, and complications. RESULTS: Between January 2023 and December 2024, twenty patients were treated (median age 87 years, range 53-93); 95% were ASA III. Most tumours were T1-T2 hormone receptor-positive carcinomas (median size 1.7 cm). Procedures were successfully completed under local or monitored anaesthesia in 95%, with 45% discharged the same day. Median ice-ball diameter was 5.3 cm, achieving 100% complete ablation. Complications were minor (10% superficial frost injury). At one year, most patients showed no recurrence except one developed multifocal disease outside the ablation zone. CONCLUSION: Cryoablation is a safe, well-tolerated, and effective palliative option for local control of breast cancer in elderly or frail patients unfit for surgery.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.